Introduction/Purpose Flow Disruption with WEB is an innovative endovascular approach for wide-neck bifurcation aneurysms that has been evaluated in 3 European Good Clinical Practice Studies: WEBCAST (WEB Clinical Assessment of Intrasaccular Aneurysm), French Observatory, and WEBCAST-2. This treatment is associated with a high safety and efficacy at one year.1 Long-term anatomical results have been very few evaluated. The present work is presenting the 2-years safety and efficacy results in the 3 GCP studies.
Materials and methods Out of the 168 patients with 169 aneurysms initially included in the 3 GCP studies, 138 patients were clinically evaluated at 2 years and 120 patients with 121 aneurysms were evaluated by vascular imaging.
Results There was no bleeding/rebleeding or thromboembolic complication between 1 year and 2 years. Morbidity and mortality at 2 years were 1.4% (2/138) and 5.1% (7/138), respectively. Two deaths (1.4%) were related to the procedure (retroperitoneal hematoma and brainstem compression). The other deaths were unrelated to the disease or the procedure (cancer: 3 patients; pneumonia: 1 patient; cirrhosis: 1 patient). Anatomical results at 2 years were complete occlusion in 62/121 aneurysms (51.2%), neck remnant in 36/121 aneurysms (29.8%), and aneurysm remnant in 23/121 aneurysms (19.0%). Anatomical results were similar in aneurysms treated with WEB DL and WEB SL/SLS. Between 1 and 2 years, aneurysm occlusion was stable or improved in 103/119 aneurysms (86.6%). Aneurysm retreatment was performed in 14 aneurysms (9.3%), 11 between the procedure and 1 year and in 3 between 1 and 2 years.
Conclusion The great safety and efficacy of WEB aneurysm treatment is confirmed at 2 years follow-up. No adverse events are observed between 1 year and 2 years. Adequate occlusion is observed in a similar percentage of aneurysms at 1 year (79.1%) and 2 years (81.0%). 1 Pierot L, Soize S, Molyneux A, Byrne J, Spelle. Evaluation of the Safety and Efficacy of Aneurysm Treatment with WEBTM device in the cumulated population of 3 prospective, multicenter series (WEBCAST, French Observatory, WEBCAST-2). J NeuroIntervent Surg. 2018;10:553–559.
Disclosures L. Pierot: 2; C; Balt, Medtronic, Microvention, Phenox, Vesalio. X. Barreau: None. I. Szikora: None. D. Herbreteau: None. J. Byrne: None. L. Spelle: None.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.